Allergan takes Linzess on a run with differentiation push

Carly Helfand Every drugmaker wants to find differentiators for their products. And for Ironwood, it was obvious. "Is this a constipation drug that improves abdominal symptoms, ...

ArGEN-X pulls in €16M to push cancer, autoimmune programs to clinical POC

Nick Paul Taylor Federated Investors has bought an 8.6% stake in arGEN-X. The deal sees arGEN-X sell shares worth €16 million ($ 17.5 million) to the major U.S. asset manager, ...

Chinese advisers push for tougher generics quality standards

Carly Helfand China's political advisers are encouraging domestic generic drug development–but at the same time, they're also pushing for tougher quality standards. On ...

Stepped-up Nucynta sales push starts paying off for Depomed

Tracy Staton Depomed's relaunch of the Nucynta franchise–purchased earlier this year from Johnson & Johnson–is off to a running start, the company said last week ...

UPDATED: Melinta’s CEO steps down amid a big Phase III push

Damian Garde Melinta Therapeutics CEO Mary Szela has left the company in the middle of a late-stage program for its lead antibiotic, a move that comes just months after the biotech ...

Neos pulls off a $72M IPO to push its ADHD drugs forward

Damian Garde Texas biotech Neos Therapeutics cleared $ 72 million in an IPO, raising cash to develop some reformulated takes on existing drugs for ADHD. FierceBiotech News

Shire’s binge-eating push on Vyvanse feeds Q1 earnings beat

Carly Helfand When Vyvanse in February won the FDA's first-ever approval for binge eating disorder (BED), Shire predicted the indication could help the med rake ...

Novartis makes concerted push into Israeli biotech startup scene

Nick Paul Taylor Over the past year, Novartis has struck a pair of deals in Israel, snagging an option to buy Gamida Cell and a stake in BioLineRx. FierceBiotech News

Trans-Pacific Partnership push waits on cue from Obama’s India visit

EJ Lane SINGAPORE–India is not a member of the 12-nation Trans-Pacific Partnership, but its intellectual property rules governing pharmaceutical patents lie at the core of a dispute ...

AbbVie urges shareholders to push Shire toward deal talks

Carly Helfand With time running out for AbbVie to strike a deal with Shire before it will have to walk away for as long as 6 months under U.K. takeover law, the Illinois-based company ...

Aventis spinout Scynexis plots a $55M IPO to push an ex-Merck antibiotic

Damian Garde Durham, NC's Scynexis is queuing up for a $ 55 million IPO, looking to ride the wave of biotech bullishness and raise cash for its in-development anti-infective. FierceBiotech ...

U.K. watchdogs push India’s Wockhardt to recall 5 drugs

Tracy Staton U.K. regulators have changed their mind about the need for a Wockhardt recall. The Medicines and Healthcare products Regulatory Agency asked Indian drugmaker Wockhardt to ...
Page 1 of 212
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS